Horng Min Leou, MD
Internal Medicine · Redmond, WANPI 1427083419
Payments from drug & device makers
Across 257 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- AstraZeneca$822
- AbbVie$532
- Kowa Pharmaceuticals America, Inc.$423
- Novo Nordisk$359
- Astellas Pharma US Inc$261
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,39899%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 43 | $1,184 |
| AstraZeneca | 46 | $822 |
| AbbVie(2 entities) | 25 | $532 |
| Kowa Pharmaceuticals America, Inc. | 18 | $423 |
| Novo Nordisk | 21 | $359 |
| Astellas Pharma US Inc | 9 | $261 |
| Lilly USA, LLC | 11 | $190 |
| Amarin Pharma, Inc. | 6 | $115 |
| GSK | 6 | $109 |
| Gilead | 5 | $106 |
| Hologic Sales And Service, LLC | 2 | $103 |
| Boehringer Ingelheim | 5 | $102 |
| Novartis | 5 | $98 |
| Pfizer | 5 | $79 |
| Shield Therapeutics Inc | 3 | $79 |
| Teva Pharmaceuticals USA, Inc. | 4 | $76 |
| Merck | 5 | $72 |
| Johnson & Johnson | 3 | $68 |
| Seqirus USA Inc | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $59 |
| IBSA Pharma Inc. | 3 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $55 |
| Exact Sciences | 2 | $52 |
| Genentech USA, Inc. | 3 | $51 |
| Amgen | 2 | $46 |
| Dexcom, Inc. | 1 | $45 |
| Sanofi Pasteur Inc. | 2 | $44 |
| Boston Scientific | 1 | $36 |
| Bayer | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| Biogen | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Linus Health, Inc. | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $12 |
How this compares
$5,478 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 26 | $47,117 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $3,243 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,108 |
| Tamsulosin Hcl | 149 | $1,895 |
| Omeprazole | 96 | $1,753 |
| Losartan Potassium | 175 | $1,526 |
| Telmisartan | 26 | $1,251 |
| Gabapentin | 55 | $1,249 |
| Levothyroxine Sodium | 137 | $1,160 |
| Amlodipine Besylate | 118 | $1,141 |
| Zolpidem Tartrate | 63 | $912 |
| Atorvastatin Calcium | 109 | $903 |
| Glyburide-Metformin HclGlyburide/Metformin Hcl | 21 | $825 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $825 |
| Rosuvastatin Calcium | 91 | $816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $359 | $47,11726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Redmond
- Gurinder SahiRedmond$42K
- Sabrina BenjaminOlympia$7.9M
- Ryan AhernSeattle$7.3M
- Eric KleinOlympia$2.4M
- Scott RamseySeattle$2M
- Vidya MenonTacoma$1.8M
- Peter ShalitSeattle$1.8M
- Yuan Po TuEverett$1.6M
- Peiqing QianSeattle$1.5M
- Radica AlicicSpokane$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.